<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Pharmacology Unit 2 ANS and Respiratory Drugs by </title>
      <link>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4</link>
      <description></description>
      <language>en-us</language>
      <pubDate>2020-06-21 16:28:15 UTC</pubDate>
      <lastBuildDate>2020-06-21 18:43:39 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Two Divisions of ANS</title>
         <author>lesliewilcox</author>
         <link>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635146685</link>
         <description><![CDATA[<div>1. <strong>Sympathetic</strong>-<strong><em>Adrenergic </em></strong>(fight,fright,flight)<br>2. <strong>Parasympathetic</strong>-<strong><em>Cholinergic</em></strong> (rest and digest)<br><br>Sources: Hitner, Henry; Nagle, Barbara. "Pharmacology: An Introduction" 7th Edition, 2016, McGraw-Hill Education LLC. <br>Marieb, Elaine; Hoehn, Katja. "Human Anatomy and Physiology" 11th Edition, 2019, Morton Publishing Company. </div>]]></description>
         <enclosure url="" />
         <pubDate>2020-06-21 16:31:28 UTC</pubDate>
         <guid>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635146685</guid>
      </item>
      <item>
         <title>Neurotransmitters</title>
         <author>lesliewilcox</author>
         <link>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635150119</link>
         <description><![CDATA[<div>1. <strong>B-1</strong>: NE and EPI<br>2. <strong>B-2</strong>: EPI<br>3. <strong>a-1</strong>: NE and EPI<br>4. <strong>d-1</strong>: dapamine at low, B-1 at moderate, A-1 at high<br>5. <strong>N-1</strong>: ACH<br>6. <strong>N-2</strong>: ACH<br>7. <strong>Muscarinic</strong>: ACH<br><br>Sources: Hitner, Henry; Nagle, Barbara. "Pharmacology: An Introduction" 7th Edition, 2016, McGraw-Hill Education LLC. <br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2020-06-21 16:36:42 UTC</pubDate>
         <guid>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635150119</guid>
      </item>
      <item>
         <title>Locations of Neurotransmitter release</title>
         <author>lesliewilcox</author>
         <link>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635152013</link>
         <description><![CDATA[<div>1. <strong>B-1</strong>: NE- released at postganglionic nerve endings, EPI- released by adrenal medulla<br>2. <strong>B-2</strong>: EPI- released by adrenal medulla<br>3. <strong>a-1</strong>:  NE- released at postganglionic nerve endings, EPI- released by adrenal medualla<br>4.<strong> d-1:</strong> dopamine- precursor to NE, sympathetic and CNS neurotransmitter, stimulates many recepotrs (alpha, beta, domapniergic)<br>5. <strong>N-1</strong>: ACH- released at ganglia from presynaptic nerve endings (both systems)<br>6. <strong>N-2</strong>: ACH- released at ganglia from presynaptic nerve endings( both systems)<br>7. <strong>Muscarinic:</strong> ACH- released at ganglia from presynaptic nerve endings (both systems)<br><br>Sources: Hitner, Henry; Nagle, Barbara. "Pharmacology: An Introduction" 7th Edition, 2016, McGraw-Hill Education LLC. <br><br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2020-06-21 16:39:56 UTC</pubDate>
         <guid>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635152013</guid>
      </item>
      <item>
         <title>Receptors for Neurotransmitters </title>
         <author>lesliewilcox</author>
         <link>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635164478</link>
         <description><![CDATA[<div><strong>ACH</strong>: <strong>Cholinergic-</strong> <em>Nicotinic</em> and <em>Muscarinic</em><br><strong>NE and EPI</strong>: <strong>Adrenergic</strong>- <em>B-1, B-2, a-1, a-2<br><br></em>Sources: Hitner, Henry; Nagle, Barbara. "Pharmacology: An Introduction" 7th Edition, 2016, McGraw-Hill Education LLC. <br>Marieb, Elaine; Hoehn, Katja. "Human Anatomy and Physiology" 11th Edition, 2019, Morton Publishing Company. </div>]]></description>
         <enclosure url="" />
         <pubDate>2020-06-21 16:58:52 UTC</pubDate>
         <guid>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635164478</guid>
      </item>
      <item>
         <title>End Organ Responses</title>
         <author>lesliewilcox</author>
         <link>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635165607</link>
         <description><![CDATA[<div><strong>ACH</strong>: <strong>Cholinergic</strong><strong><em>- Nicotinic</em></strong>: neuromusculare junctions of skeletal muscle; excitation-contraction of muscle <strong><em> Muscarinic</em></strong>: All parasympathetic target organs; inhibitation of cardiac muscle, excitation in most cases<br><strong>NE and EPI</strong>: <strong>Adrenergic</strong><strong><em>- B-1:</em></strong> heart, but also kidneys and adipose tissue; increases heart rate and force of contraction, stimulates kidneys to release renin   <strong><em>B-2</em></strong>: lungs, smooth muscle, skeletal muscle arteries, cornary arteries   <strong><em> a-1</em></strong>:  smooth muscle, eyes, most arteries and veins; constricts blood vessels and visceral organ sphincters, dilates pupils of eyes   <strong><em>a-2</em></strong>: adenergic axon terminals ; inhibits NE release from adrenergic axon terminals  <br><br>Sources: Hitner, Henry; Nagle, Barbara. "Pharmacology: An Introduction" 7th Edition, 2016, McGraw-Hill Education LLC. <br>Marieb, Elaine; Hoehn, Katja. "Human Anatomy and Physiology" 11th Edition, 2019, Morton Publishing Company. <br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2020-06-21 17:00:38 UTC</pubDate>
         <guid>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635165607</guid>
      </item>
      <item>
         <title>Drug Classifications </title>
         <author>lesliewilcox</author>
         <link>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635172119</link>
         <description><![CDATA[<div><strong>Alpha-1 Adrenergic Agonist</strong>: alpha-1 receptor is stimulated, contraction of smooth muscle, blood vessels constrict, increase blood pressure, vasoconstriction of nasal passages, decongestant effect <br>Adrenergic Agonist: stimulates all alpha and beta receptors, increases blood pressure<br><br><strong>Alpha-1 Adrenergic Antagonists(Blocker, Inhibitor)</strong>: bind to alpha-1 receptors and blocks them, relaxation of smooth muscle, vasodilation of blood vessels, decreases blood pressure<br><br><strong>Beta-1 Adrenergic Agonists</strong>: low dose: stimulates dopaminegic (d-1) receptors in kidneys causing vasodilation and increased renal blood flow; moderate dose: stimulates beta-1 receptors on heart, increases force of contraction and cardiac output; high dose: stimulates alpha-1 receptors causing vasoconstriction, increases blood pressure<br><br><strong>Beta-2 Adrenergic Agonists</strong>: stimulate beta-2 adrenergic receptors, smooth muscle relaxation, promote bronchodilation, relieve bronchospasms <br><br><strong>Beta-Adrenergic Antagonists(Blocker, Inhibitor)</strong>:<strong><em> Selective Beta-1 Blockers</em></strong>- block beta-1 receptors, decreases force of contraction, decrease cardiac output, decrease heart rate, decrease conduction, decrease blood pressure<br><strong>Beta-Adrenergic Antagonist(Blocker, Inhibitor)</strong>: <strong><em>Non-Selective Beta-1 Blockers</em></strong>- blocks beta-1 and beta-2 receptors, decreases force of contraction, decrease cardiac output, decrease heart rate, decrease conduction, decrease blood pressure<br><br><strong>Direct Acting Cholinergic Agonists</strong>: directly stimulate/bind to the muscarinic receptors in the parasympathetic division, mimics ACH<br><br><strong>Indirect Acting Cholinergic Agonists</strong>: inhibit actelycholinesterase, the enzyme that destroys ACH in the synapses, increases ACH <br><br><strong>Anticholinergic</strong>: bind to a cholinergic receptor, acts as a blocking drug<br><br><strong>Skeletal Muscle Relaxants</strong>: <br><strong>Peripherally Acting</strong>:<br><em>Depolarizing Agents</em><strong>-</strong> binds to Nicotinic 2/Nm receptors and induces depolarization, alters Nicotinic 2/Nm receptor so it cannot respond to ACH and prevent contractions  <br><em>Non-Depolarizing Agents-</em> occupies the Nicotinic 2/Nm receptor sites, ACH cannot bind, no contraction, no depolarization <br> <em>Direct Acting Agents-</em> inhibits skeletal muscle contractions, blocks Ca++ release within the muscle fiber, does NOT affect Nicotinic 2/Nm receptor or spinal cord conduction  <br><strong>Centrally Acting Agents</strong><strong><em>: </em></strong>decreases number of impulses available to produce a contraction at motor neurons, block conduction within the spinal cord<br><br>Sources: Hitner, Henry; Nagle, Barbara. "Pharmacology: An Introduction" 7th Edition, 2016, McGraw-Hill Education LLC. <br>Marieb, Elaine; Hoehn, Katja. "Human Anatomy and Physiology" 11th Edition, 2019, Morton Publishing Company. </div>]]></description>
         <enclosure url="" />
         <pubDate>2020-06-21 17:09:40 UTC</pubDate>
         <guid>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635172119</guid>
      </item>
      <item>
         <title>Drug Examples</title>
         <author>lesliewilcox</author>
         <link>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635196863</link>
         <description><![CDATA[<div><strong>Alpha-1 Adrenergic Agonist</strong>: ephedrine, phenylephrine (Neo-Synephrine ®)<br><br><strong>Adrenergic Agonist</strong>: epinephrine (Adrenalin ®)<br><br><strong>Alpha-1 Adrenergic Blockers</strong>: prazosin (Minipress ®), terazosin (Hytrin ®), doxazosin (Cardura ®)<br><br><strong>Beta-1 Adrenergic Agonist</strong>: dobutamine <br><br><strong>Beta-2 Adrenergic Agonist</strong>: formoterol (Foradil ®), albuterol (Proventil ®, Ventolin ®), terbutaline (Brethine ®)<br><br><strong>Beta-Adrenergic Blockers</strong>: <strong><em>Selective Beta-1 Blockers</em></strong>: atenolol (Tenomin ®), metoprolol (Lopressor ®)   <br><strong><em>Non-Selective Beta-1 Blocker</em></strong>: nadolol (Corgard ®), propranolol (Inderol ®), tomolol (Blocadren ®) <br><br><strong>Direct Acting Cholinergic Agonist</strong>: acetylcholine, pilocarpine (Pilocar ®), bethanechol (Urecholine ®)<br><br><strong>Indirect Acting Cholinergic Agonist</strong>: neostigmine (Prostigmin ®)<br>Anticholinergic: atropine, dicyclomine (Bentyl ®)<br><br><strong>Skeletal Muscle Relaxants</strong>: <br><strong>Peripherally Acting-</strong><br><em>Depolarizing Agent</em>: succinylchoine<br><em>Non- Depolarizing Agent</em>: rocuronium bromide (Zemuron ®)<br><em>Direct Acting Agent</em>: dantrolene (Dantrium ®)<br><strong>Centrally Acting-</strong> cyclobenzaprine (Flexeril ®), carisoprodol (Soma ®), methocarbamol (Robanix ®), orphenadrine citrate (Norflex ®), chlorzoxazone (Parafon Forte DSC ®), metaxalone (Skelaxin ®)<br> <br>Sources: Hitner, Henry; Nagle, Barbara. "Pharmacology: An Introduction" 7th Edition, 2016, McGraw-Hill Education LLC. <br>             </div>]]></description>
         <enclosure url="" />
         <pubDate>2020-06-21 17:46:58 UTC</pubDate>
         <guid>https://padlet.com/lesliewilcox/8fp8bv9p9etwihp4/wish/635196863</guid>
      </item>
   </channel>
</rss>
